Emergence of Extremely Drug Resistant and Pan Drug Resistant Acinetobacter baumanii and Pseudomonas aeruginosa Isolated from Diverse Samples in Delhi

Puneeta Singh¹, Vandana Lal² and Shalabh Malik^1,

¹Department of Microbiology and Serology, Dr Lal Path Labs National Reference Laboratory, Delhi, India

²Dr Lal Path Labs National Reference Laboratory, Delhi, India

Cite this paper:
Puneeta Singh, Vandana Lal and Shalabh Malik. Emergence of Extremely Drug Resistant and Pan Drug Resistant Acinetobacter baumanii and Pseudomonas aeruginosa Isolated from Diverse Samples in Delhi. American Journal of Infectious Diseases and Microbiology. 2020; 8(4):132-138. doi: 10.12691/ajidm-8-4-3

Abstract

Aims and objectives: The purpose of this study is to observe the recent prevalence to assess drug resistance pattern of Extremely-drug resistant (XDR) and Pan drug resistant (PDR) isolates of Acinetobacter baumanii and Pseudomonas aeruginosa among clinically diagnosed cases from diverse samples in Dr Lal Path Labs, Delhi. Materials and Methods: Retrospective analysis of XDR and PDR resistance in 1655 isolates of Acinetobacter baumanii and 4238 isolates of Pseudomonas aeruginosa considered between one-year period March 2019-2020, performed at Microbiology department of Dr Lal Path Labs. Identification was carried out by MALDI-TOF and antimicrobial susceptibility was evaluated by VITEK® 2 with respective susceptibility card (AST 281, BioMerieux, India) as per as CLSI M100-S-29. Results: This Retrospective study conducted to analyse XDR resistance prevalence among 258 (15.6%) in Acinetobacter baumanii and 512 (12.1%) in Pseudomonas aeruginosa isolates from various clinical specimens. Of the1655 total isolates 41, (2.5%) of Acinetobacter baumanii and 4328 total isolates 166, (3.8%) of Pseudomonas aeruginosa were resistant to all available antibiotics (Pan Drug Resistant). Variability of Acinetobacter baumanii XDR isolates was seen in different sample type that is pus (23.8%), respiratory (21.8%), fluid (21.2%), whereas XDR Pseudomonas aeruginosa was largely isolated from fluid (15.1%), followed by urine (12.8%), pus (11.4%). PDR strains of both species were isolated from respiratory and urine specimens. The other variable included in this study was impact of age with respective of isolates detection. The most predominant age group infected with Acinetobacter baumanii were Young adults (<=21-40 years) constituted 37.2% while in Pseudomonas aeruginosa constituted 46.4% elderly adults (≥ 60 years of age) of all isolates. Conclusion: XDR and PDR isolates of Acinetobacter baumanii and Pseudomonas aeruginosa become more virulent; is a reality and leading to clinical treatment failure leaving very few or no treatment options in our hand. XDR and PDR has become the concern for policy makers and urgent need of strictly adhere to the concept of reserve drugs policy, to minimize the misuse of available antimicrobial Colistin in our country.

Keywords:
Extremely drug resistant (XDR) Pan drug Resistant (PDR) Colistin Acinetobacter baumanii Pseudomonas aeruginosa

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Arroyo LA, Mateos I, Gonzalez V, Aznar J. “In vitro activities of tigecycline, minocycline and colistin- tigecycline combination against multi and pandrug resistant clinical isolates of Acinetobacter baumanii group”. Antimicrob Agents Chemother. 53: 1295- 6. 2009.
[2]	Cai Y, Chai D, Wang R, Liang B, Bai N. “Colistin resistance of Acinetobacter baumanii: Clinical reports, mechanisms and antimicrobial strategies”. J Antimicrob Chemother. 67(7): 1607-1615. 2012.
[3]	Gales AC, Jones RN, Sader HS. “Global assessment of antimicrobial activity of polymixin B against 54,731 clinical isolates of Gram-negative bacilli: Report from the SENTRY antimicrobial surveillance programme (2001-2004)”. Clin Microbiol infect. 12: 315-21. 2006.
[4]	Manchanda V, Sinha S and Singh NP. “Multidrug Resistant Acinetobacter”. J Glob Infect Dis. Sep-Dec; 2(3): 291-304. 2010.
[5]	Maragakis LL, Perl TM. “Acinetobacter baumanii: epidemiology, antimicrobial resistance and treatment options”. Clin Infect Dis. 46:1254-63. 2008.
[6]	Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. “Colistin-resistant Acinetobacter baumannii: Beyond carbapenem resistance”. Clin Infect Dis. 60: 1295-303. 2015.
[7]	Willyard C. “The drug-resistant bacteria that pose the greatest health threats”. Nature. 543: 15. 7. 2017.
[8]	Grewal US, Bakshi R, Walia G, Shah PR. “Antibiotic susceptibility profiles of non-fermenting gram-negative Bacilli at a Tertiary Care Hospital in Patiala, India”. Niger Postgrad Med J. 24: 121-5. 2017.
[9]	Al-Sweih NA, Al-Hubail MA, Rotimi VO. “Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals”. J Chemother. 23: 13-6. 2011.
[10]	Abhijit S. Nair. Minocycline: “The second important antimicrobial in multidrug-resistant Acinetobacter baumanii infections”. J Anaesthesiol Clin Pharmacol. 34(1): 140-141p. Jan-Mar; 2018.
[11]	Maraki S, Mantadakis E, Mavromanolaki V.E, Kofteridis D, Samonis G. “A. 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital”. Infect. Chemother. 48: 190-198. 2016.
[12]	Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. “Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case-control study”. Crit Care Med. 36: 807-11. 2008.
[13]	Moazami-Goudarzi S, Eftekhar F. “Assessment of carbapenem susceptibility and multidrug resistance in Pseudomonas aeruginosa in burn isolates”. Jundishapur J Microbiol. 6: 162-5. 2012.
[14]	Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS. “Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016)”. Int J Antimicrob Agents. 51: 848-53. 2018.
[15]	Bassetti M, Peghin M, Vene A and Giacobbe DR. “Treatment of Infectious due to MDR Gram-Negative bacteria”. Front. Med. 6: 74. 2019.
[16]	Basak S, Singh P and Rajurkar M. “Multidrug resistant and extensively drug resistant Bacteria: A study”. J Pathog. 4065603. 2016.
[17]	Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, et al. “Informing antibiotic treatment decisions: Evaluating rapid molecular diagnostics to identify susceptibility and resistance to carbapenems against Acinetobacter spp”. In PRIMERS III. J Clin Microbiol. 55: 134-44. 2017.
[18]	Gill J S, Arora S, Khanna SP, Kumar KH. “Prevalence of multidrug resistant, extensively drug- resistant, and pandrug- resistant Pseudomonas aeruginosa from a tertiary level intensive Care Unit”. J Global Infect Dis. 8: 155-9. 2016.
[19]	Rajalakshmi Arjun, Ram Gopalakrishnan, P. Senthur Nambi, D. Suresh Kumar, R. Madhumitha, and V. Ramasubramanian. “A Study of 24 Patients with Colistin-Resistant Gram-negative Isolates in a Tertiary Care Hospital in South India”. Indian J Crit Care Med. May; 21(5): 317-321. 2017.
[20]	Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. “Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: Results from the SENTRY surveillance program (2010-2013)”. Diagn Microbiol Infect Dis. 83:183-6. 2015.
[21]	Veeraraghavan B, Pragasam A.K, Bakthavatchalam Y D, Anandan S et al., “Colistin sparing approaches with newer antimicrobials to treat carbapenem resistant organisms; Current evidence and future prospects”. Indian J Med Microbiol. 37: 72-90. 2019.
[22]	Srivastava G, Bhatambare G S, Patel K B. “Evaluation of prevalence and antibiogram of Multidrug resistant, extensively drug resistant and pan drug resistant Pseudomonas aeruginosa in patients visiting a tertiary care hospital in central India”. CHRISMED Journal of Health and Research. 1(3):145-149. 2014.
[23]	Taneja N, Singh G, Singh M, Sharma M. “Emergence of tigecycline and colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in North India”. Indian J Med Res. 133 (6): 681-684. 2011.
[24]	Vakili B, Fazeli H, Shoaei P, Yaran M, Ataei B et al. “Detection of colistin sensitivity in clinical isolates of Acinetobacter baumanii in Iran”. J Res Med Sci. 19 (suppl 1): S67-S70. 2014.
[25]	Goli HR, Nahaei MR, Rezaee MR, Hasani A, Kafil HS, Aghazadeh M. “Colistin resistant Pseudomonas aeruginosa at Tabriz hospitals, Iran”. Iran J Microbiol. 8(1): 62-69. 2016.
[26]	Safaei H J, Moghim S, Isfahani B N, Fazeli H et al., “Distribution of the strains of Multidrug resistant, Extensively Drug resistant and Pandrug resistant Pseudomonas aeruginosa isolates from burn patients”. Adv Biomed Res. 6: 74. 2017.